TP53 and hepatocellular carcinoma: It is currently unclear whether cuproptosis affects HCC patients’ sensitivity to sorafenib or the other biological features of these patients, for example, lower mutant frequency of TP53 (Figure 5C) (62, 63), contribute to such a resistance.